Lars Fruergaard Jørgensen, who has led the pharmaceutical giant since 2017, joined the firm in 1991. View on euronews ...

Meanwhile, Eli Lilly's Zepbound injection has gained traction, prompting both firms to race toward more convenient ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound Eli Lilly's stock wobbled Thursday after a looming coverage hit was ...

Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial.

Eli Lilly said that it planned to seek regulatory approval to market the drug for weight loss later this year, and early next year for diabetes. The F.DA. could take months and possibly longer to ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...

Eli Lilly ( NYSE: LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's ( ...

Eli Lilly shares jumped ... s clinical trial registry, Lilly’s primary obesity trial is not expected to conclude until at least July. An oral version of weight loss drugs could pose a threat ...

Eli Lilly stock surged as much as 17% after positive phase-three trial data came out for orforglipron. It found orforglipron, a GLP-1 weight-loss pill, led to significant weight and A1C reductions.

Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.